Overall, the investigator-assessed confirmed ORR in NSCLC patients with RET fusion-positive was 26.8% (95%CI 18.3–36.8%), the DCR was 72.2% (95%CI 62.1–80.8%), and 26 (26.8%) patients with a partial response (PR) (Supplementary Table 9). Here, RET is linked to non-small cell lung carcinoma.